These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 30478125)
1. Patient-reported gout attack frequency and allopurinol use in general practice in the Netherlands: a prospective observational cohort study protocol. van Leeuwen KDB; Bohnen AM; Jacobs ML; van Der Lei J; Janssens HJEM; Koffeman AR; Bindels PJE; Bierma-Zeinstra SMA BMJ Open; 2018 Nov; 8(11):e024335. PubMed ID: 30478125 [TBL] [Abstract][Full Text] [Related]
2. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. Hill EM; Sky K; Sit M; Collamer A; Higgs J J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090 [TBL] [Abstract][Full Text] [Related]
3. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969 [TBL] [Abstract][Full Text] [Related]
4. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. Robinson PC; Taylor WJ; Dalbeth N J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513 [TBL] [Abstract][Full Text] [Related]
5. Gout, flares, and allopurinol use: a population-based study. Proudman C; Lester SE; Gonzalez-Chica DA; Gill TK; Dalbeth N; Hill CL Arthritis Res Ther; 2019 May; 21(1):132. PubMed ID: 31151457 [TBL] [Abstract][Full Text] [Related]
6. Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study). Stamp L; Te Karu L; Reid S; Wright DFB; Frampton C; Tuitaupe VS; Dalbeth N BMJ Open; 2024 Aug; 14(8):e084665. PubMed ID: 39097306 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KD; Portek I; WIlliams KM; Westbrook JI BMJ Open; 2017 Oct; 7(10):e017281. PubMed ID: 29042386 [TBL] [Abstract][Full Text] [Related]
8. [Summary of the Dutch College of General Practitioners' "Gout" Standard]. Romeijnders AC; Gorter KJ Ned Tijdschr Geneeskd; 2002 Feb; 146(7):309-13. PubMed ID: 11876034 [TBL] [Abstract][Full Text] [Related]
9. Gout characteristics associate with depression, but not anxiety, in primary care: Baseline findings from a prospective cohort study. Prior JA; Mallen CD; Chandratre P; Muller S; Richardson J; Roddy E Joint Bone Spine; 2016 Oct; 83(5):553-8. PubMed ID: 27068619 [TBL] [Abstract][Full Text] [Related]
10. Achieving treat to target in gout: a clinical practice improvement project. Lim AY; Shen L; Tan CH; Lateef A; Lau TC; Teng GG Scand J Rheumatol; 2012; 41(6):450-7. PubMed ID: 22839705 [TBL] [Abstract][Full Text] [Related]
11. [Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up]. Eliseev MS; Barskova VG; Denisov IS Ter Arkh; 2015; 87(5):10-15. PubMed ID: 26155614 [TBL] [Abstract][Full Text] [Related]
12. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. Neogi T; Hunter DJ; Chaisson CE; Allensworth-Davies D; Zhang Y J Rheumatol; 2006 Jan; 33(1):104-9. PubMed ID: 16267879 [TBL] [Abstract][Full Text] [Related]
13. A pilot study of CXCL8 levels in crystal proven gout patients during allopurinol treatment and their association with cardiovascular disease. Kienhorst L; Janssens H; Radstake T; van Riel P; Jacobs J; van Koolwijk E; van Lochem E; Janssen M Joint Bone Spine; 2017 Dec; 84(6):709-713. PubMed ID: 27894951 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Singh JA; Akhras KS; Shiozawa A Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969 [TBL] [Abstract][Full Text] [Related]
15. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Roddy E; Zhang W; Doherty M Ann Rheum Dis; 2007 Oct; 66(10):1311-5. PubMed ID: 17504843 [TBL] [Abstract][Full Text] [Related]
16. The management of gout in different clinical specialties in Turkey: a patient-based survey. Öztürk MA; Mercan R; Gök K; Onat AM; Kısacık B; Kimyon G; Balkarlı A; Kaya A; Çobankara V; Balcı MA; Pamuk Ö; Yıldırım Çetin G; Sayarlıoğlu M; Şenel S; Tezcan ME; Küçük A; Üreten K; Şahin Ş; Tufan A Clin Rheumatol; 2016 Dec; 35(12):3019-3024. PubMed ID: 27722972 [TBL] [Abstract][Full Text] [Related]
17. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922 [TBL] [Abstract][Full Text] [Related]
18. Adherence and persistence to urate-lowering therapies in the Irish setting. McGowan B; Bennett K; Silke C; Whelan B Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858 [TBL] [Abstract][Full Text] [Related]
19. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase. Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297 [TBL] [Abstract][Full Text] [Related]
20. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Taylor TH; Mecchella JN; Larson RJ; Kerin KD; Mackenzie TA Am J Med; 2012 Nov; 125(11):1126-1134.e7. PubMed ID: 23098865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]